Zevra Therapeutics Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -88.0% | +51.8% | +230.7% | -72.1% | +22.9% | +412.1% | -1.1% | -83.6% | +31.4% | +53.6% | -67.2% | +121.1% | -19.3% | +37.0% | +166.7% | -65.8% | +18.3% | +29.9% | -16.9% | +225.9% | +69.4% | +26.9% | +0.7% | +30.9% | +6.1% | +9.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | +94.5% | -65.9% | -3.2% | – | – | – | +0.0% | – | – | -86.4% | +537.5% | +176.5% | +1.4% | -12.6% | +441.6% | -78.7% | +2,167.4% | +9.4% | -35.5% | -40.7% | -1.5% | +820.4% | -87.5% | -2.1% | +49.0% | -32.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -105.4% | – | +339.4% | -69.3% | +22.9% | +369.9% | -1.2% | -82.1% | +28.4% | +56.8% | -68.4% | +118.8% | -20.4% | +40.2% | +155.4% | -64.7% | -94.2% | +447.5% | +58.9% | +667.0% | +78.5% | -29.1% | +81.5% | +33.0% | +4.1% | +12.3% | – | |
| – | -14.1% | +86.0% | -48.4% | +13.0% | +35.3% | -12.0% | +110.2% | -9.9% | +27.1% | -52.7% | +35.3% | -43.7% | -24.7% | -31.8% | -13.8% | -8.1% | -12.5% | +78.7% | -25.8% | +25.7% | -21.4% | +25.5% | +9.7% | +628.7% | -76.0% | +110.0% | -23.5% | -14.1% | +65.4% | -12.9% | -1.8% | +4.0% | -9.4% | -67.1% | +5.4% | 0.0% | -23.7% | +67.6% | +2.1% | – | |
| – | -27.6% | -7.3% | +13.5% | +9.4% | -7.1% | -21.2% | +19.8% | +9.2% | -12.5% | -0.9% | -4.3% | +5.3% | +20.9% | -61.9% | +63.2% | -23.4% | -16.9% | +76.9% | -25.2% | +21.8% | -15.5% | +31.2% | +7.0% | +30.1% | +11.7% | +27.8% | +34.6% | +2.5% | -16.9% | +70.7% | -83.8% | +910.5% | -90.1% | +1,118.5% | +6.3% | -18.5% | +20.2% | +2.1% | -20.3% | – | |
| – | +12.1% | +4.3% | -32.0% | +11.4% | +16.9% | -15.2% | +81.2% | -5.8% | +17.4% | -43.2% | +22.7% | -31.5% | -7.2% | -46.9% | +35.4% | -29.4% | -14.6% | +77.8% | -25.5% | +24.0% | -18.7% | +28.1% | +8.4% | +347.3% | -64.0% | +22.1% | +39.0% | -11.6% | +29.0% | +14.0% | +19.5% | +16.3% | -9.1% | -6.4% | +246.2% | -75.9% | +14.4% | +8.1% | -15.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -236.4% | – | – | -146.8% | – | – | -16.2% | -138.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +124.8% | -5.2% | +90.0% | – | |
| – | -2.0% | +0.3% | -0.3% | +0.1% | +0.3% | -0.3% | -0.1% | -1.3% | -6.4% | +3.5% | -12.5% | +0.2% | +2.7% | +18.0% | -1.8% | -3.3% | -1.7% | -7.4% | -78.3% | -92.8% | -76.0% | -16.7% | +0.0% | +620.0% | +244.4% | +37.1% | +7.1% | +8.2% | +85.8% | +100.8% | +187.1% | +9.6% | -5.1% | -10.3% | +2.0% | +2.1% | -5.0% | -12.2% | -100.0% | – | |
| – | -237.6% | – | – | – | – | – | – | – | – | – | – | – | – | -297.2% | – | – | -454.2% | – | – | – | -128.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -101.3% | – | +253.7% | -71.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -366.7% | – | -3.3% | -101.9% | – | -82.3% | -113.7% | – | +466.7% | -111.8% | – | – | – | – | – | – | -139.5% | – | – | – | -92.3% | +86.0% | -119.7% | – | +1,280.0% | -41.5% | – | |
| – | -255.4% | – | – | – | – | – | – | – | – | – | – | – | – | -322.4% | – | – | -450.3% | – | – | – | -128.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.7% | – | +211.5% | -76.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -224.0% | – | – | -145.8% | – | – | – | -126.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | +4,636.4% | -98.2% | +921.6% | +190.2% | -69.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.